Prescriptions for EpiPen alternatives such as Kaléo Inc.‘s Auvi-Q device have quadrupled since the beginning of this year, according to data from the Athenahealth Network. The demand for cheaper alternative devices is likely driven by revelations that Mylan (NSDQ:MYL) hiked the price of its EpiPen emergency allergy injector by 500% since it acquired the device in 2007.
Generic options for the injector were sparse until Kaleo’s product was re-released in mid-February this year. Mylan launched a generic version of its own device in December last year at half the price of the original and CVS said in January that it will stock Impax Laboratories‘'(NSDQ:IPXL) $10 EpiPen alternative known as Adrenaclick.
Get the full story at our sister site, Drug Delivery Business News.